[{"address1": "201 Haskins Way", "city": "South San Francisco", "state": "CA", "zip": "94080", "country": "United States", "phone": "650 695 0677", "website": "https://lyell.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.", "fullTimeEmployees": 224, "companyOfficers": [{"maxAge": 1, "name": "Dr. Richard D. Klausner M.D.", "age": 71, "title": "Founder & Executive Chairman", "yearBorn": 1952, "fiscalYear": 2023, "totalPay": 80000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Lynn  Seely M.D., Ph.D.", "age": 64, "title": "President, CEO & Director", "yearBorn": 1959, "fiscalYear": 2023, "totalPay": 962226, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Charles W. Newton", "age": 52, "title": "Chief Financial Officer", "yearBorn": 1971, "fiscalYear": 2023, "totalPay": 744737, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Stephen J. Hill", "age": 53, "title": "Chief Operating Officer", "yearBorn": 1970, "fiscalYear": 2023, "totalPay": 775967, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Gary  Lee Ph.D.", "age": 46, "title": "Chief Scientific Officer", "yearBorn": 1977, "fiscalYear": 2023, "totalPay": 889676, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Matthew  Lang J.D.", "age": 47, "title": "Chief Business Officer, Chief Legal Officer & Corporate Secretary", "yearBorn": 1976, "fiscalYear": 2023, "totalPay": 596253, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Prof. Stanley R. Riddell M.D.", "title": "Founder & Scientific Advisor", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Crystal L. Mackall M.D.", "age": 62, "title": "Founder & Scientific Advisor", "yearBorn": 1961, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Nellie  Dillery", "title": "Director of Accounting", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Ellen  Rose", "title": "Senior Vice President of Communications & Investor Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 3, "boardRisk": 8, "compensationRisk": 10, "shareHolderRightsRisk": 8, "overallRisk": 10, "governanceEpochDate": 1727740800, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 1.15, "open": 1.14, "dayLow": 1.12, "dayHigh": 1.17, "regularMarketPreviousClose": 1.15, "regularMarketOpen": 1.14, "regularMarketDayLow": 1.12, "regularMarketDayHigh": 1.17, "beta": -0.538, "forwardPE": -1.3068181, "volume": 289738, "regularMarketVolume": 289738, "averageVolume": 631285, "averageVolume10days": 438450, "averageDailyVolume10Day": 438450, "marketCap": 294403456, "fiftyTwoWeekLow": 1.06, "fiftyTwoWeekHigh": 3.256, "priceToSalesTrailing12Months": 5451.916, "fiftyDayAverage": 1.3023, "twoHundredDayAverage": 1.9211, "currency": "USD", "enterpriseValue": -136494416, "floatShares": 165285850, "sharesOutstanding": 256003008, "sharesShort": 10657278, "sharesShortPriorMonth": 13764836, "sharesShortPreviousMonthDate": 1724976000, "dateShortInterest": 1727654400, "sharesPercentSharesOut": 0.0416, "heldPercentInsiders": 0.15336001, "heldPercentInstitutions": 0.67084, "shortRatio": 12.84, "shortPercentOfFloat": 0.0591, "bookValue": 2.213, "priceToBook": 0.51965654, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -210259008, "trailingEps": -0.83, "forwardEps": -0.88, "pegRatio": 0.18, "enterpriseToRevenue": -2527.674, "enterpriseToEbitda": 0.668, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "LYEL", "underlyingSymbol": "LYEL", "shortName": "Lyell Immunopharma, Inc.", "longName": "Lyell Immunopharma, Inc.", "firstTradeDateEpochUtc": 1623936600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "c5ad7970-8aa2-3c85-a7aa-1e907d8cc7ab", "gmtOffSetMilliseconds": -14400000, "currentPrice": 1.15, "targetHighPrice": 6.0, "targetLowPrice": 1.0, "targetMeanPrice": 3.67, "targetMedianPrice": 4.0, "recommendationMean": 2.5, "recommendationKey": "buy", "numberOfAnalystOpinions": 3, "totalCash": 491119008, "totalCashPerShare": 1.918, "ebitda": -204470000, "totalDebt": 60221000, "quickRatio": 15.905, "currentRatio": 16.187, "totalRevenue": 54000, "debtToEquity": 10.63, "returnOnAssets": -0.18845, "returnOnEquity": -0.32264, "freeCashflow": -87023504, "operatingCashflow": -158431008, "revenueGrowth": -0.519, "grossMargins": 1.0, "operatingMargins": -3963.6921, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-10-24"}]